含力克肺疾、左氧氟沙星加母牛分枝杆菌菌苗方案治疗耐多药肺结核的临床研究  

Clinical research on the scheme of Pasiniazid,Levofloxacin and cows Mycobacterium bacterial vaccine in treatment of multidrug resistant Pulmonary Tuberculosis

作　　者：罗凯 

机构地区：[1]玉林市结核病防治所,广西玉林537000

出　　处：《临床肺科杂志》2012年第2期290-291,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨耐多药肺结核患者采用力克肺疾、左氧氟沙星、吡嗪酰胺、丙硫异烟胺、丁胺卡那霉素、母牛分枝杆菌菌苗治疗疗效。方法对2006年2月～2008年2月我所收治的耐多药肺结核患者63例进行分析。结果临床症状明显改善,肺部病灶吸收率达93.65%;治疗三个月末痰菌阴转率为47.62%,满疗程痰菌阴转率73.02%,空洞闭合率66.67%;随访6～24个月痰菌复发率为4.76%。结论本方案治疗耐多药肺结核效果满意,药物副作用小,可用于临床治疗耐多药肺结核患者。Objective To discuss the clinical effects of 3 pasiniazid, levofloxacin, pyrazinamide, protionamide, amikacin and cows mycobacterium bacterial vaccine/18 pasiniazid,levofloxacin and protionamide on muhidrug resistant Pulmonary Tuberculosis. Methods Clinical data of 63 patients with muhidrug resistant Pulmonary Tuberculosis admitted in our hospital from Feb. 2006 to Feb. 2008 were analyzed. Results Clinical symptoms improved, and the rate of pulmonary lesions absorption reached 93.65%. After three month treatment, sputum negative conversion rate was 47.62% ;After the full course of treatment, sputum negative conversion rate was 73.02% ; The rate of cavity closure was 66. 67%. The recurrence rate of sputum bacteria was 4.76% after following up for 6 -24 months. Conclusions This scheme has satisfactory effect on muhidrug resistant Pulmonary Tuberculosis and less side effects, which can be used for clinical treatment.

关 键 词：耐多药性 母牛分枝杆菌菌苗 力克肺疾 左氧氟沙星 

分 类 号：R521[医药卫生—内科学]